Treatment effects in pediatric soft tissue and bone tumors: Practical considerations for the pathologist

American Journal of Clinical Pathology

Volumn 123, Issue 1, 2005, Pages 75-90

  Coffin, Cheryl M ^a,b   Lowichik, Amy ^a   Zhou, Holly ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Ewing sarcoma; Infantile fibrosarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Synovial sarcoma; Therapy induced cytodifferentiation; Treatment effects

Indexed keywords

ALPHA ACTIN; ANTINEOPLASTIC AGENT; CAFFEINE DERIVATIVE; CD45 ANTIGEN; CD68 ANTIGEN; CD99 ANTIGEN; DESMIN; GLYCOPROTEIN P; MYOD1 PROTEIN; MYOGENIN;

BONE TUMOR; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD CARE; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL PROTOCOL; DIFFERENTIAL DIAGNOSIS; EVALUATION; EWING SARCOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MEDICAL DECISION MAKING; NEUROECTODERM TUMOR; NORTH AMERICA; OSTEOSARCOMA; OUTCOMES RESEARCH; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; STANDARDIZATION; SURVIVAL RATE; SYNOVIAL SARCOMA; TECHNIQUE; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 11244336678     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/H0D4VD760NH6N1R6     Document Type: Review

References (114)

1. Ries L, Smith M, Gurney J, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. Bethesda, MD: National Institutes of Health; 1999.
2. Brenner H. Up-to-date survival curves of children with cancer by period analysis. Br J Cancer. 2003;88:1693-1697.
3. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
4. Fletcher CDM, Unni KK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002. World Health Organization Classification of Tumours.
5. Fletcher CDM, Unni KK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002. World Health Organization Classification of Tumours.
6. Lowichik A, Zhou H, Pysher TJ, et al. Therapy associated changes in childhood tumors. Adv Anat Pathol. 2000;7:341-359.
7. Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61-72.
8. Vander Griend RA. Osteosarcoma and its variants. Orthop Clin North Am. 1996;27:575-581.
9. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212-236.
10. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
11. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
12. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
13. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: The Memorial Hospital experience. Cancer. 1992;69:698-708.
14. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
15. Ham SJ, Schraffordt Koops H, van der Graaf WT, et al. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol 1998;24:584-600.
16. Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am. 1990;72:643-653.
17. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
18. Saeter G, Elomaa I, Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl. 1997;273:156-160.
19. Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? a study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2001;38:1218-1225.
20. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97:3068-3075.
21. Bacci G, Picci P, Mercuri M, et al. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Acta Oncol. 1998;37:671-676.
22. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma: a meta-analysis. Cancer. 2003;98:581-589.
23. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003;21:536-542.
24. Sluga M, Windhager R, Lang S, et al. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop. 1999;358:120-127.
25. Patterson K. The pathologic handling of skeletal tumors. Am J Clin Pathol. 1998;109(4suppl 1):S53-S66.
26. Wold LE. Practical approach to processing osteosarcomas in the surgical pathology laboratory. Pediatr Dev Pathol. 1998;1:449-454.
27. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
28. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-1521.
29. Ayala AG, Raymond AK, Jaffe N. The pathologist's role in the diagnosis and treatment of osteosarcoma in children. Hum Pathol. 1984;15:258-266.
30. Weatherby RP, Unni KK. Practical aspects of handling orthopedic specimens in the surgical pathology laboratory. Pathol Annu. 1982;17(pt 2):1-31.
31. Willen H. Tumor necrosis and prognosis in osteosarcoma. Acta Orthop Scand Suppl. 1997;273:126-129.
32. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003;228:271-278.
33. Coffin C. Pediatric Soft Tissue Tumors. Baltimore, MD: Williams & Wilkins; 1997.
34. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020-1033.
35. Dorfman H, Czerniak B. Ewing's sarcoma and related entities. In: Bone Tumors. St Louis, MO: Mosby; 1998:607-661.
36. Granowetter L, West DC. The Ewing's sarcoma family of tumors: Ewing's sarcoma and peripheral primitive neuroectodermal tumor of bone and soft tissue. Cancer Treat Res. 1997;92:253-308.
37. Delepine N, Delepine G, Cornille H, et al. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J Chemother. 1997;9:352-363.
38. Sauer R, Jurgens H, Burgers JM, et al, for the Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Prognostic factors in the treatment of Ewing's sarcoma. Radiother Oncol. 1987;10:101-110.
39. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European Cooperative Trial. Cancer. 1988;61:23-32.
40. Akerman M. Tumour necrosis and prognosis in Ewing's sarcoma. Acta Orthop Scand Suppl. 1997;273:130-132.
41. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11:1763-1769.
42. Ferrari S, Mercuri M, Rosito P, et al. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother. 1998;10:484-491.
43. Nilbert M, Saeter G, Elomaa I, et al. Ewing's sarcoma treatment in Scandinavia 1984-1990: ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol. 1998;37:375-378.
44. Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998;16:3044-3052.
45. Abudu A, Davies AM, Pynsent PB, et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br. 1999;81:317-322.
46. Hoffmann C, Ahrens S, Dunst J, et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer. 1999;85:869-877.
47. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4-11.
48. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
49. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999;86:421-428.
50. Jenkin RD, Al-Fawaz I, Al-Shabanah M, et al. Localised Ewing sarcoma/PNET of bone; prognostic factors and international data comparison. Med Pediatr Oncol. 2002;39:586-593.
51. de Stefani E, Carzoglio J, Deneo Pellegrini H, et al. Ewing's sarcoma: value of tumor necrosis as a predictive factor. Bull Cancer. 1984;71:16-21.
52. Terrier P, Henry-Amar M, Triche TJ, et al. Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? Eur J Cancer. 1995;31A:307-314.
53. Aparicio J, Munarriz B, Pastor M, et al. Long-term follow-up and prognostic factors in Ewing's sarcoma: a multivariate analysis of 116 patients from a single institution. Oncology. 1998;55:20-26.
54. Llombart-Bosch A, Contesso G, Henry-Amar M, et al. Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations; a retrospective study of 261 cases. Virchows Arch A Pathol Anat Histopathol. 1986;409:627-640.
55. Daugaard S, Kamby C, Sunde LM, et al. Ewing's sarcoma: a retrospective study of histological and immunohistochemical factors and their relation to prognosis. Virchows Arch A Pathol Anat Histopathol. 1989;414:243-251.
56. Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol. 1999;32:186-195.
57. Ozaki T, Lindner N, Hoffmann C, et al. Ewing's sarcoma of the ribs: a report from the cooperative Ewing's sarcoma study. Eur J Cancer. 1995;31A:2284-2288.
58. Lang P, Vahlensieck M, Matthay KK, et al. Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Med Pediatr Oncol. 1996;26:329-333.
59. Kobayashi Y, Ozaki T, Takeda Y, et al. Evaluation of the effect of preoperative chemotherapy in bone sarcomas: 99mTc-HMDP scintigraphy in 34 cases. Acta Orthop Scand. 1998;69:611-616.
60. van der Woude HJ, Bloem JL, van Oostayen JA, et al. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. AJR Am J Roentgenol. 1995;165:125-133.
61. Kinoshita T, Tatezaki S, Matsuzoki O, et al. Ultrasonographic monitoring of the effects of preoperative chemotherapy in osteosarcoma and Ewing's sarcoma. Int Orthop. 1995;19:312-314.
62. Huvos A. Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd ed. Philadelphia, PA: Saunders; 1991.
63. Salzer-Kuntschik M, Delling G, Beron G, et al. Morphological grades of regression in osteosarcoma after polychemotherapy: study COSS 80. J Cancer Res Clin Oncol. 1983;106(suppl):21-24.
64. Ushigome S, Shimoda T, Nikaido T, et al. Primitive neuroectodermal tumors of bone and soft tissue: with reference to histologic differentiation in primary or metastatic foci. Acta Pathol Jpn. 1992;42:483-493.
65. Maeda G, Masui F, Yokoyama R, et al. Ganglion cells in Ewing's sarcoma following chemotherapy: a case report. Pathol Int. 1998;48:475-480.
66. Collini P, Mezzelani A, Modena P, et al. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. Am J Surg Pathol. 2003;27:1161-1166.
67. Rosolen A, Favaretto G, Masarotto G, et al. Effects of all-trans retinoic acid and interferon alpha in peripheral neuroectodermal tumor cell cultures and xenografts. Int J Oncol. 1998;13:943-949.
68. Harms D. Soft tissue sarcomas in the Kiel Pediatric Tumor Registry. Curr Top Pathol. 1995;89:31-45.
69. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998;1:550-561.
70. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas; pathologic aspects and proposal for a new classification: an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76:1073-1085.
71. Stout A. Rhabdomyosarcoma of the skeletal muscles. Cancer. 1946;123:447-472.
72. Horn RC Jr, Enterline HT. Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases. Cancer. 1958;11:181-199.
73. Caillaud JM, Gerard-Marchant R, Marsden HB, et al. Histopathological classification of childhood rhabdomyosarcoma: a report from the International Society of Pediatric Oncology Pathology Panel. Med Pediatr Oncol. 1989;17:391-400.
74. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma; a new classification scheme related to prognosis. Arch Pathol Lab Med. 1992;116:847-855.
75. Asmar L, Gehan EA, Newton WA, et al. Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas: report of an international study of four pathology classifications. Cancer. 1994;74:2579-2588.
76. Gonzalez Montalvo P, Jaffe N, Farzin E. Relapse eighteen and one-half years after apparent cure of sarcoma botryoides of the vagina [letter]. Med Pediatr Oncol. 2003;41:178-179.
77. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence: results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer. 1998;34:1050-1062.
78. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997;19:483-491.
79. Douglass EC, Shapiro DN, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol. 1993;21:83-87.
80. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
81. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995;13:2123-2139.
82. Kelly KM, Womer RB, Barr FG. Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer. 1996;78:1320-1327.
83. Heyn R, Newton WA, Raney RB, et al. Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol. 1997;15:69-75.
84. Molenaar WM, Oosterhuis JW, Kamps WA. Cytologic " differentiation" in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol. 1984;15:973-979.
85. d'Amore ES, Tollot M, Stracca-Pansa V, et al. Therapy associated differentiation in rhabdomyosarcomas. Mod Pathol. 1994;7:69-75.
86. Coffin CM, Rulon J, Smith L, et al. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol. 1997;10:1175-1187.
87. Smith LM, Anderson JR, Coffin CM. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol. 2002;38:398-404.
88. Atra A, Ward HC, Aitken K, et al. Conservative surgery in multimodal therapy for pelvic rhabdomyosarcoma in children. Br J Cancer. 1994;70:1004-1008.
89. Eusebi V, Ceccarelli C, Gorza L, et al. Immunocytochemistry of rhabdomyosarcoma; the use of four different markers. Am J Surg Pathol. 1986;10:293-299.
90. Guillou L, Coquet M, Chaubert P, et al. Skeletal muscle regeneration mimicking rhabdomyosarcoma: a potential diagnostic pitfall. Histopathology. 1998;33:136-144.
91. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? a study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol. 2001;25:1150-1157.
92. Skytting B. Synovial sarcoma: a Scandinavian Sarcoma Group project. Acta Orthop Scand Suppl. 2000;291:1-28.
93. Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999;32:32-37.
94. Spillane AJ, A'Hem R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18:3794-3803.
95. Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol. 2001;37:90-96.
96. Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602-1161.
97. Willett CG, Schiller AL, Suit HD, et al. The histologic response of soft tissue sarcoma to radiation therapy. Cancer. 1987;60:1500-1504.
98. Tsuchiya H, Tomita K, Yamamoto N, et al. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. Anticancer Res. 1998;18:3651-3656.
99. Coffin CM, Jaszcz W, O'Shea PA, et al. So-called congenital-infantile fibrosarcoma: does it exist and what is it? Pediatr Pathol. 1994;14;133-150.
100. Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer. 1976;38:729-739.
101. Cecchetto G, Carli M, Alaggio R, et al. Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979-1995). J Surg Oncol. 2001;78:225-231.
102. Kurkchubasche AG, Halvorson EG, Forman EN, et al. The role of preoperative chemotherapy in the treatment of infantile fibrosarcoma. J Pediatr Surg. 2000;35:880-883.
103. Loh ML, Ahn P, Perez-Atayde AR, et al. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol 2002;24:722-726.
104. Shetty AK, Yu LC, Gardner RV, et al. Role of chemotherapy in the treatment of infantile fibrosarcoma. Med Pediatr Oncol. 1999;33:425-427.
105. McCahon E, Sorensen PH, Davis JH, et al. Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol. 2003;40:288-292.
106. Ferguson WS. Advances in the adjuvant treatment of infantile fibrosarcoma. Expert Rev Anticancer Ther. 2003;3:185-191.
107. Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000;24:937-946.
108. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184-187.
109. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451-1458.
110. Schofield DE, Reicher JA, Grier HE, et al. Fibrosarcoma in infants and children: application of new techniques. Am J Surg Pathol. 1994:18:14-24.
111. Desbois JC, Delepine G, Cornille H, et al. Congenital fibrosarcoma: a case for neoadjuvant chemotherapy [abstract], Med Pediatr Oncol. 1991;19:366.
112. Kynaston JA, Malcolm AJ, Craft AW, et al. Chemotherapy in the management of infantile fibrosarcoma. Med Pediatr Oncol. 1993;21:488-493.
113. Renard M, Brock P, Kruger M, et al. Chemotherapy in congenital fibrosarcoma [abstract]. Med Pediatr Oncol. 1991;19:362.
114. Ninane J, Gosseye S, Panteon E, et al. Congenital fibrosarcoma: preoperative chemotherapy and conservative surgery. Cancer. 1986;58:1400-1406.